New CEO – new chapter
MC2 Therapeutics A/S, a Hørsholm-based pharmaceutical company focused on topical therapies in inflammatory skin conditions, announced the appointment of Trine Ahlgreen as Chief Executive Officer at the end of May.
The appointment marking a new chapter in the company’s journey. Ahlgreen brings an extensive background to MC2 Therpaeutics, spanning commercial leadership of global, regional and local pharmaceutical product launches, leadership of several successful cross-functional teams and business development across Europe, the US and Japan.
She played key roles in several high-impact product launches at Novo Nordisk. Most recently, at Swiss biotech Micreos Pharmaceuticals AG, Ahlgreen built the commercial and business development infrastructure focused on dermatology, forging valuable strategic partnerships across both pharma and OTC.
MC2 Therapeutics’ proprietary PAD TechnologyTM is an innovative formulation and delivery system for management of chronic dermatologic conditions.
Bild von freepik
Novo Nordisk
By Benff - Own work, CC BY-SA 4.0, https://commons.wikimedia.org/w/index.php?curid=128081038